Medicine · 2020
Next-generation sequencing identified a novel DYSF variant in a patient with limb-girdle muscular dystrophy type 2B: A case report.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Qiao, Tan Cheng, Chen Jiajun, Zhang Lei
Аннотация
RATIONALE: Limb-girdle muscular dystrophy (LGMD) is a genetic disease, which is characterized by muscle atrophy and weakness mainly involving proximal muscles. Accurate diagnosis of LGMD patient is very important for the appropriate management and long-term prognosis.
PATIENT CONCERNS: An 18-year-old woman presented with progressive weakness of limbs, persistent elevated serum creatine kinase, myogenic damages in electromyography, and dysferlin protein deficiency in muscle biopsy. Further next-generation sequencing (NGS) revealed a compound heterozygous variant in dysferlin gene (DYSF), including a novel frameshift variant of c.4010delT.
DIAGNOSIS: The patient was diagnosed with LGMD2B clinically and genetically.
INTERVENTIONS: Oral levocarnitine and coenzyme Q10 were prescribed to the patient.
OUTCOMES: After symptomatic treatments for 1 week, the patient's symptoms were not improved.
LESSONS: NGS might be a helpful tool for the diagnosis of LGMD. A novel variant of c.4010delT in DYSF was identified in this case, which broadens the genetic spectrum of LGMD2B.
PATIENT CONCERNS: An 18-year-old woman presented with progressive weakness of limbs, persistent elevated serum creatine kinase, myogenic damages in electromyography, and dysferlin protein deficiency in muscle biopsy. Further next-generation sequencing (NGS) revealed a compound heterozygous variant in dysferlin gene (DYSF), including a novel frameshift variant of c.4010delT.
DIAGNOSIS: The patient was diagnosed with LGMD2B clinically and genetically.
INTERVENTIONS: Oral levocarnitine and coenzyme Q10 were prescribed to the patient.
OUTCOMES: After symptomatic treatments for 1 week, the patient's symptoms were not improved.
LESSONS: NGS might be a helpful tool for the diagnosis of LGMD. A novel variant of c.4010delT in DYSF was identified in this case, which broadens the genetic spectrum of LGMD2B.